Filing Flows › Senti Biosciences Holdings (SNTI) › Q2 2026
Senti Biosciences Holdings (SNTI) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 14, 2026
Senti Biosciences Holdings (SNTI) reported revenue of $17K for the second quarter 2026 (Q2 2026) and +6% from the quarter before.
Senti Biosciences Holdings, Q2 2026: revenue $17K, net loss $12.8M, operating cash flow −$14.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17K | +6% | — |
| Operating profit | −$14.5M | — | — |
| Net earnings | −$12.8M | — | — |
| Operating cash flow | −$14.2M | — | — |
What changed
Revenue was $17K in Q2 2026, up 6% from the previous quarter.
Operating costs exceeded revenue by $14.5M, an operating margin of -85229.4%. The quarter ended with a net loss of $12.8M, wider than the previous quarter's $4.2M loss.
Operating cash flow was −$14.2M. Non-cash charges added back $667K of depreciation and $1.0M of share-based compensation. Working capital and other items used $3.2M.
Questions
What was Senti Biosciences Holdings' revenue in the second quarter 2026?
Senti Biosciences Holdings (SNTI) reported revenue of $17K for the second quarter 2026 (Q2 2026) and +6% from the quarter before.